Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Increasing hepatitis C treatment may curb hepatocellular carcinoma

Key clinical point: The incidence of HCV-related hepatocellular carcinoma dropped from 2015 to 2018 after initiation of a hepatitis C treatment effort.

Major finding: The incidence of HCV-related HCC declined among VHA patients from a peak of 31.0 per 100,000 patients in 2015 to 21.8 per 100,000 in 2018.

Study details: The data come from a review of all patients with a diagnosis of hepatocellular carcinoma between 2002 and 2018 based on electronic health records.

Disclosures: The study was supported in part by grants from the National Institutes of Health/National Cancer Institute and the Veterans Affairs Clinical Science Research and Development. The researchers had no financial conflicts to disclose.

Citation:

Beste LA et al. JAMA. 2020 Sep 8;324(10):1003-5.